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When attacked by a new enemy, do not forget the old ones. 
A tale of 2 diseases: tuberculosis and COVID-19
Dear Editor
COVID-19 (COrona VIrus Diagnosed in 2019) 
is the most important health crisis of the present 
generation. Tuberculosis (TB) was overtaken by 
COVID-19 on April 1st, 2020 as the leading cause 
of death per day by an infectious disease. India 
is home to more than a quarter of the world’s TB 
population and is presently ranked fourth in the 
number of cases of COVID-19 after the United 
States, Brazil, and Russia. The regions with the 
largest tuberculosis burden are also the areas most 
affected by the COVID-19 pandemic [1].
COVID-19 and TB have both overloaded the 
health system and both need a quick reliable 
diagnosis and a robust treatment plan due to 
the fact that both have a high fatality rate. Ad-
ditionally, they have social stigmas attached to 
them upon diagnosis or suspicion of diagnosis 
and need increased public awareness to mitigate 
this. Transmission for both of these diseases is 
via droplets. One COVID-19 infected patient 
can infect 2.5 people in 5 days (i.e. R0 = 5), but 
diligent isolation can decrease this rate to as 
low as 1.05. Meanwhile, one TB infected patient 
can infect 10–15 people per year [1]. A delay in 
diagnosis of both can prove to be disastrous. Un-
treated, TB is a slow progressive disease which 
is unlike COVID-19. However, a delay in diag-
nosis and/or treatment non-compliance adds to 
the morbidity and mortality of these which is 
further complicated by the development of drug 
resistance. An important difference between the 
two is that, unlike tuberculosis, COVID-19 has 
gained much needed attention, has strong health 
surveillance systems which monitor and track the 
epidemic alongside national policies that were 
implemented in order to contain the epidemic. 
Both these diseases have the ability to affect 
each other’s pathogenesis as both are implicated 
in severely disturbing the hosts innate immune 
response. Co-infection with COVID-19 and tu-
berculosis has also been reported recently [2]. 
SARS-COV-2 infection can happen simultane-
ously, precede, or follow a tuberculosis diagnosis 
[3]. Tuberculosis has also been implicated to 
increase the vulnerability to this new corona-
virus infection as well as its severity [4]. As the 
clinical manifestations are similar, the current 
care of patients with TB has been severely affected 
amidst the current pandemic. Strong adminis-
trative commitment with good political support 
was needed immediately and it was taken up by 
Indian government to curtail the pandemic to 
some extent. Measures taken included interstate 
coordination, awareness via social media, social 
isolation, tracking down suspected cases, a coun-
trywide lockdown, and timely mobilization of 
essential goods. Unfortunately, these measures 
have severely hampered the ongoing tuberculosis 
care which was already suffering. The most sig-
nificant issues include diagnosis and management 
of new cases, continuance of treatment of already 
diagnosed (particularly drug-resistant cases) due 
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to the nation-wide lockdown, lack of timely phy-
sician access, transportation of drugs, nutritional 
and mental health support, and clinical care for 
comorbidities like HIV and cancer. These can lead 
to not only a worsening of the active tuberculosis 
burden, but also activation of latent tuberculo-
sis cases. Transmission of tuberculosis among 
household members is also affected due to less 
exposure to tuberculosis preventative treatment 
because of limited health care access.
Apart from diagnosis and treatment, another 
important development regarding tuberculosis 
that occurred as result of this pandemic is acute 
mass migration, especially migrant labourer, due 
to the nationwide lockdown and subsequent 
loss of jobs. Migrants carry with them infections 
and pathogens which is presently proving to 
be a new challenge in the containment of the 
COVID-19 virus, and will result in the same 
challenge in the future for tuberculosis [5]. The 
migration phenomenon coupled with worsening 
socio-economic standards make them vulnera-
ble for tuberculosis infection in the future [6]. 
A newly issued statement by the WHO regarding 
the anticipation of a secondary tuberculosis emer-
gency in the near future may not be wrong and 
they stress the importance of making sure that 
TB services continue uninterrupted during the 
COVID-19 pandemic [7]. It should be remembered 
that diluted attention to existing TB management 
services due to the diversion of resources towards 
this new pandemic can result in an increase in 
drug-resistant cases and the eventual crumbling 
of the health care system. 
Fi g h t i n g  t u b e r c u l o s i s  a m i d s t  t h e 
COVID-19 pandemic needs interventions at mul-
tiple levels. Socio-economic support in the form 
of monetary funds and food parcels, especially for 
those without jobs, will help as poverty is known 
to drive tuberculosis rates globally. Infection 
control measures which are being propagated for 
COVID-19 can provide a much needed boost for 
preventing tuberculosis spread as well and can 
result in hindering practices like spitting, tobacco 
chewing, etc. Digital technology used to improve 
infection control measures and offer psychological 
support may also help. The surveillance and test-
ing of high risk patients, especially members of the 
same household, has also improved by quantifying 
risk using simple tools for risk stratification [8]. 
Non-governmental organizations (NGO) offering 
more access to laboratory and health care workers 
with proper protection may help. Integration of 
COVID-19 and tuberculosis services is paramount 
now. Tuberculosis survivors and those having 
active tuberculosis should be prioritized for 
COVID-19 testing as they are especially vulnerable 
for the SARS-CoV-2 infection due to chronic lung 
damage and decreased cell-mediated immunity. 
The risk of progression from latent tuberculosis 
infection to active disease may increase due to 
COVID-19. Hence, COVID-19 testing should be 
used as an opportunity to detect tuberculosis 
latent infections in certain defined vulnerable 
groups. Further, having a low threshold for com-
puted tomography (CT) chest and tubercle bacilli 
testing for COVID-19 patients may help in diag-
nosing subclinical chronic active tuberculosis 
patients [9]. An integrated testing system for 
both diseases with further decentralisation of 
tuberculosis testing along with drug sensitivity 
might be a pertinent solution. Continuing the 
already strengthened BCG vaccination program 
in the country will help as it has been shown that 
COVID-19 related mortality is strongly associated 
with BCG vaccination national programs [10].
Conclusion
Tubeculosis has long been a cause for sig-
nificant morbidity and mortality in some coun-
tries. Emerging new diseases, such as COVID-19, 
should not let loosen our grip on it. Infection 
control measures and cough etiquettes propagated 
amidst this pandemic can prove to be a turning 
point in controlling the spread of TB. An inte-
grated health care approach is in utmost need in 
order to tackle the menace of tuberculosis during 
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